For low risk profile Antiphospolipid syndrome (only one cardiolipin Ab or beta 2 GPI Ab positivity, but not positive lupus anticoagulant: high risk) may be treated with DOAC with precaution as described in the recently published article. ashpublications.org/blood/article/142/Supplement%201/2651/502130/Clinical-Characteristics-and-Anticoagulation-Use#

Lazertinib in combination with amivantamab was approved by FDA for advanced/metastatic NSCLC with EGFR (+) for exon 19 deletion or L585R substitution mutation. Lazertinib is a new 3rd generation EGFR TKI. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer 4:58

Thanks Dr. Kim. I have one "H" variant, detected on my 23 & Me genetic tests, but they don't test for all variants. At 59, I started having severe G.I. issues, fatigue, and surprised that a CT showed an enlarged liver. I don't drink, never did drugs, tested negative numerous times for all Hep strains and serous viruses. My ferratin was 202. I never eat red meat, nor take iron supplements. With one positive variant, and European decent, how to diagnose or rule out Hemochromatosis? An iron test years ago was also super high...like 1500, but he doctor then said it was "a lab error".

This is so helpful -- thank you!

Adjuvant radiation therapy (ART) in breast cancer conservation therapy for stage 1-2 patients (<70 y/o) may not help: after 30 years of follow up, it only reduced local recurrence in the same breast for the first 10 years (16 be 36%), but not thereafter. And it did not improve the overall survival rate. www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00347-4/abstract

Osimertinib prolonged DFS to 40 months in EGFR exon 19 deletion or L858R mutation positive Stage III NSCLC after concurrent chemo-radiation therapy (LAURA 3 trial) --> Osimertinib 80 mg QD until disease progression: new guidelines ascopubs.org/doi/10.1200/JCO-24-01324 www.nejm.org/doi/10.1056/NEJMoa2402614

OPRA trial update The 3-year probability of OP (organ preservation: no surgery) was 77% (95% CI, 70%-85%) for patients with a CCR (clinical complete response) and 40% (95% CI, 32%-51%) for patients with an NCR (near complete response) (P < .001). jamanetwork.com/journals/jamanetworkopen/fullarticle/2813744

Thank you very much Sir

Cholngiocarcinoma with lung metastasis life expectancy?

thank you it's very clear!

Triple negative breast cancer stage 1 may not need neoadjuvant or adjuvant chemotherapy if stromal tumor infiltrating lymphocytes (TIL) are over 50%. jamanetwork.com/journals/jamaoncology/article-abstract/2820527

Thank you so much. This video was very useful to review my knowledge. Well explained.

Starting low doses of lenvatinib (with pembrolizumab) did not improve 6 month disease progression rate or drug discontinuation rate. www.mdalert.com/ms/endometrial-cancer/article/lower-dose-lenvatinib-pfs-discontinuation-rates?uid=ABB0E610A5EB13C6BDD2AEAA206F450B&uac=289993FT&uid_npi=1306940705&ET&seg=&sso=true

I would like to clarify RxPonder Trial by SWOG: In ER+ HER2- LN1-3 + early breast cancer and Oncotype DX RE 0-25: Post menopausal women: endocrine Tx alone (no benefit by adding chemotherapy. However, premenopausal women need endocrine and chemotherapy as the combination of endocrine and chemotherapy improved DFS.

FDA approved SQ daratumumab + VRD for the first induction therapy in stem cell transplant eligible patients: it showed better PFS.patients also had consolidation therapy with Dara + lenalidomide for 2 yrs, then lenalidomide alone. www.nejm.org/doi/full/10.1056/NEJMoa2312054

Exemestane + ovarian suppression is better than tamoxifen + ovarian suppression or tamoxifen alone in premenopausal ER+ HER2- early invasive lobular breast cancer www.medscape.com/viewarticle/exemestane-plus-ovarian-suppression-best-early-invasive-2024a10009tv However, it is not clear if patients with invasive ductal breast cancer can have de-escalated therapy such as tamoxifen alone.

New immuno-chemotherapy for advanced endometrial cancer 1. Pembrolizumab + carboplatin and paclitaxel regardless of MMR status 2. Durbalumab + carboplatin and paclitaxel for MMR deficient metastatic endometrial cancer www.mdalert.com/ms/endometrial-cancer/article/fda-approves-new-immunotherapy-regimens?uid=ABB0E610A5EB13C6BDD2AEAA206F450B&uac=289993FT&uid_npi=1306940705&ET&seg=&sso=true

NADINA trial: Neoadjuvant Dual Immunotherapy Improves EFS in Stage III Melanoma meetings.asco.org/abstracts-presentations/234897

After neoadjuvant therapy for early HER2 (+) breast cancer, breast conservation therapy provides better overall survival than mastectomy among patients who achieved pathological complete response (pCR) in the axillary lymph nodes. But among patients with pCR in the breast, the survival did not differ. www.thelancet.com/journals/lanam/article/PIIS2667-193X(24)00039-5/fulltext#%20

Was recently diagnosed with CML in June of 24. I am currently on 140mg Sprycel a day. I return tomorrow the oncologist on the 20th of August and am hoping to have that dose reduced. What determines whether the doctor puts you on Gleevec or Sprycel? If Gleevec has a better long term outcome, wouldn’t it be prescribed over Sprycel? Just curious what determines the choice for the prescribing physician.

PostMONARCH trial: abemaciclib + fulvestrant is better than placebo + fulvestrant for ER + HER2- metastatic breast cancer progressed over previous CDK4/6 inhibitor plus endocrine therapy. ORR16%, PFS at 6 Mon. 50%. www.medscape.com/s/viewarticle/abemaciclib-combo-improves-survival-advanced-breast-cancer-2024a1000anu?ecd=WNL_clinicdgst_240731_MSCPPERSO_6712876_pos1&uac=289993FT&impID=6712876&form=fpf

FDA approved Guardant Shield blood test for colorectal cancer screening. It provides 83% sensitivity. ascopost.com/news/july-2024/guardant-health-s-shield-blood-test-approved-by-the-fda-as-a-primary-screening-option-for-colorectal-cancer/

Thank you Dr. Very detailed❤

What is the probability that anisocytosis, poikilocytosis and teardrop cells in the blood is myelofibrosis

Very helpful. Thank you

thank u soooo much

the side effects will kill the patient! I would NEVER agree to this type of treatment!

Are there any studies using Metabolic Therapy for CML or AML? I started #Carnivore and my mutation load is going DOWN?

Who benefits adjuvant chemotherapy (ACT) in Stage 2 colon cancer? The updated DYNAMIC trial showed that patients with (-)ctDNA do not need ACT. meetings.asco.org/abstracts-presentations/234913

Treatment with sacituzumab tirumotecan significantly improved progression-free survival (PFS) and overall survival (OS) when compared to chemotherapy for patients with heavily pretreated, advanced triple-negative breast cancer, according to phase 3 data presented at the 2024 ASCO Annual Meeting. The antibody-drug conjugate sacituzumab tirumotecan targets TROP2, which is overexpressed in triple-negative breast cancer and often correlates with adverse outcomes. In a phase 3 study, researchers assigned 263 patients with advanced triple-negative breast cancer to monotherapy with sacituzumab tirumotecan (n = 130) or to physician’s choice chemotherapy (n = 133). The median age of the study cohort was 51 years, and the heavily pretreated population had received two or more previous therapies, including at least one therapy in the metastatic setting. In total, prior PD-1/PD-L1 inhibitors receipt was 26%, and 48% had received three or more lines of prior chemotherapy in the advanced setting. The rate of visceral metastases was 87%. PFS served as the primary endpoint. Results of an interim analysis revealed that assignment to sacituzumab tirumotecan correlated with a 69% reduction in the risk of progression or death (hazard ratio [HR] = 0.31; 95% CI, 0.22-0.45; P < .00001). The median PFS for patients assigned to sacituzumab tirumotecan was 5.7 months (95% CI, 4.3-7.2), compared to 2.3 months (95% CI, 1.6-2.7) for patients assigned to chemotherapy. The 6-month PFS rates were 43.4% and 11.1%, respectively. Among patients with a TROP2 H-score above 200, the median PFS with sacituzumab tirumotecan was 5.8 months, compared to 1.9 months for chemotherapy (HR = 0.28; 95% CI, 0.17-0.48). Median follow-up for OS was 10.4 months. The researchers observed a significant trend toward improved OS for patients assigned to sacituzumab tirumotecan (median, not reached vs 9.4 months; HR = 0.53; 95% CI, 0.36-0.78; P = .0005). The objective response rate also favored sacituzumab tirumotecan (43.8% vs 12.8%). Treatment with sacituzumab tirumotecan was well tolerated. The most common treatment-related adverse events (grade 3 or higher) included decreased neutrophil count (sacituzumab tirumotecan vs chemotherapy, 32.3% vs 47%), anemia (27.7% vs 6.1%), and decreased white blood cell count (25.4% vs 36.4%).

FDA approved repotrektinib for metastatic solid tumor with NYRK fusion. www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive#:~:text=On%20June%2013%2C%202024%2C%20the,advanced%20or%20metastatic%20or%20where

FDA approved fam-trastuzumab deruxican (Enhertu) for any solid tumor with HER2 (+). www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

FDA approved BRAF inhibitor for all solid cancer with BRAFV600E mutation. www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid

www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-ret-fusion-positive-thyroid-cancer#:~:text=On%20June%2012%2C%202024%2C%20the,and%20who%20are%20radioactive%20iodine%2D

FDA approved Selpercatinib for RET rearrangement thyroid cancer. About 20% papillary and 65% medullary thyroid cancer express RET. express RET.

Adagrasib was approved by FDA for metastatic colorectal cancer with KRAS G12C mutation. It is combined with cetuximab with 35% responses rate: www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer

Brahmi Chyawanprash for planet ayurveda It supports almost all systems of the body. It is a purely natural product and does not contain binders, preservatives, additives, yeast, and fillers in it.

Thank you immune Booster for Planet Ayurveda is a very good product for itp patient

교수님, 안녕하세요? 질문이 있어 댓글 남깁니다. 몇 년 전 유방암 1기로 방사선 치료만 했었고, 올해 유방 원발 미만성거대B세포림프종-ABC 1기 진단 받은 환우 보호자입니다. (환우 나이 만 57세) 알찹 6회+MTX 2회 진행하였고 3차 항암 후 중간검사 결과도 매우 좋았고, 항암 마친 후 최종검사했을 때 혈액은 완전 깨끗해졌다고 했습니다. 그런데 CT에는 안 보이는데 PET에서 오른쪽 난소에 뭔가 움직임이 보인다고, 이게 생리 현상인지 병인지를 모르겠으니 3개월 뒤 추적검사 때 PET를 다시 찍어보자고 하십니다. 1. 폐경 후에 난소 움직임이 보이는 게 혹시 종양 전이일 수 있는지 아니면 다른 가능성도 있을 수 있는지 궁금합니다. 전이성 종양 가능성이 있다면 3개월 기다렸다가 검사하지 않고 산부인과에서 초음파든 다른 검사든 해보는 게 나은 건 아닐까요? 왜 3개월 뒤에 추적검사 때 PET를 다시 찍어서 확인하자고 하신 걸까요? 걱정이 많이 됩니다…. 2. 유방 원발이라 뇌, 중추신경 전이 가능성이 높으니 예방적으로 MTX 3회를 하자고 하셨다가 2회만 하고 마무리하였습니다. 주치의인 교수님께서는 논문에서 MTX가 실질적인 효과가 있는지는 입증되지 않았고 전통적으로 그렇게 해왔기에 예방항암을 하는 거라서 큰 문제 없다고 하셨는데, 공격성 아형이라 더 적극적으로 해야 하는 거 아닌가 싶은데 교수님께서는 이에 대해 어떻게 보시나요? 3. 고용량 비타민C 정맥주사의 효과에 대한 논문을 보면 결론이 정반대인데 항암 종료 후에 정기적으로 맞는 거에 대해 교수님은 어떻게 생각하시는지 궁금합니다.

The only barriers to curing diseases, are lack of knowledge, skill and experience of the scientists, doctors and specialists in these fields of disease. We're interested in the curing.

I read that constantly high transferrin saturation levels can cause organ damage despite normal ferritin levels. Is this true?

Planet Ayurveda has the best ITP treatment. My platelet count has improved, and I feel great.

Imetelstat: New drug for EPO refractory MDS was approved by FDA. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imetelstat-low-intermediate-1-risk-myelodysplastic-syndromes-transfusion-dependent

We're are you located and phone numbers and address

What about THIO-101? Targeting Telomeres to Clear Cancer - Short vs Long Telomerase | Aubrey De Grey

Dr Kim… if stage 1b TNBC / lesion 8mmx4mm found ~ in rt breast ~ on routine mammogram ~ had neoadjunctice TC CHEMO prior to double Mastectomy ( profilactic ) NEG Sentinal nodes and Lymph nodes on surgical pathology report… no suspicious nodes found prior to treatment with complete tumor response to chemo….QUESTION: Sentinal Node and Lymph node biopsy ( blue dye) was done ONLY after neoadjunctive chemo… could micro seedlings of cancer cells in nodes even have been determined in said nodes if they were already dead from prior chemo therapy ⁉️⁉️ ⁉️⁉️⁉️ neoadjuctive therapy; would microseedlings to

Thank you for sharing. 5th year

The US Food and Drug Administration has granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen) for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab is a first-in-class bispecific T-cell engager (BiTE) that binds delta-like ligand 3 on the surface of cells, including tumor cells, and CD3 expressed on the surface of T-cells. It causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells, according to labeling. Approval was based on data from 99 patients in DeLLphi-301 trial with relapsed/refractory extensive-stage SCLC who had progressed after platinum-based chemotherapy Patients with symptomatic brain metastases, interstitial lung disease, noninfectious pneumonitis, and active immunodeficiency were excluded. The overall response rate was 40%, and median duration of response 9.7 months. The overall response rate was 52% in 27 patients with platinum-resistant SCLC and 31% in 42 with platinum-sensitive disease. Continued approval may depend on verification of clinical benefit in a confirmatory trial. Labeling includes a box warning of serious or life-threatening cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome. The most common adverse events, occurring in 20% or more of patients, were cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, constipation, anemia, and nausea. The most common grade 3 or 4 laboratory abnormalities included decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium. The starting dose is 1 mg given intravenously over 1 hour on the first day of the first cycle followed by 10 mg on day 8 and day 15 of the first cycle, then every 2 weeks until disease progression or unacceptable toxicity.

Thank you so much Dr kim! ❤️❤️❤️

Dr is there any merit to Dr Thomas Seyfried approach to starving cancer by depriving it of glucose and glutamine.